This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ethel Tur, MD
Department of Dermatology Ichilov Medical Center 6 Weizman St Tel Aviv, Israel 64239

Sarah Brenner, MD
Tel Aviv, Israel

Arch Dermatol. 1994;130(6):800-801.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

We appreciate the interest in our article shown by Miralles et al. Indeed, data collected so far regarding the application of low-dose recombinant interferon alfa to Kaposi's sarcoma appear inconclusive.

In a recently published report, Trattner et al¹ injected interferon alfa intralesionally, with a dosage similar to ours, resulting, most probably, in a systemic distribution. Of 10 patients, only one showed a complete resolution of all lesions following a mere 3 weeks of treatment. A response of the injected lesion was noted in all but one patient; distant lesions exhibited no effect. The patients were treated for up to 8 weeks only, and a longer period of treatment might have resulted in a more favorable response, although even much lower doses given for a similar period of time (6 to 7 weeks) in a previous study² resulted in some noticeable changes in distant lesions.

Since the submission of . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?